RT Book, Section
A1 Gill, Amitoj
A1 Gosain, Rahul
A2 Kloecker, Goetz
A2 Arnold, Susanne M.
A2 Fraig, Mostafa M.
A2 Perez, Cesar A.
SR Print(0)
ID 1176020940
T1 Immunotoxicity
T2 Lung Cancer: Standards of Care
YR 2021
FD 2021
PB McGraw-Hill
PP New York, NY
SN 9781260136203
LK hemonc.mhmedical.com/content.aspx?aid=1176020940
RD 2024/04/25
AB This  case  involves  a  68-year-old  man  diagnosed  with  metastatic  non–small  cell  lung  cancer  (NSCLC)  and  adenocarcinoma  histology  with  a  programmed  death  ligand  1  (PDL-1)  score  of  35%.  He  completed  4  cycles  of  carboplatin,  pemetrexed,  and  pembrolizumab  combination  treatment  and  is  currently  on  pemetrexed  and  pembrolizumab  maintenance  treatment.  He  presented  to  the  hospital  with  abdominal  cramps,  6-8  episodes  of  bloody  diarrhea  in  a  day,  and  fatigue.  An  infectious  etiology  has  been  ruled  out,  and  immune-related  colitis  is  speculated.  What  treatment  should  be  offered  to  this  patient?